Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E26.51 EPS (ttm)2.20 Insider Own0.10% Shs Outstand2.25B Perf Week6.26%
Market Cap131.03B Forward P/E7.93 EPS next Y7.35 Insider Trans-5.93% Shs Float2.25B Perf Month0.55%
Income3.44B PEG1.45 EPS next Q1.50 Inst Own79.60% Short Float2.01% Perf Quarter-8.78%
Sales26.15B P/S5.01 EPS this Y-33.90% Inst Trans0.02% Short Ratio2.73 Perf Half Y15.67%
Book/sh26.90 P/B2.17 EPS next Y18.28% ROA5.00% Target Price70.45 Perf Year26.69%
Cash/sh6.84 P/C8.51 EPS next 5Y18.30% ROE13.70% 52W Range42.48 - 68.34 Perf YTD-9.25%
Dividend1.80 P/FCF28.78 EPS past 5Y10.90% ROI5.50% 52W High-14.76% Beta0.71
Dividend %3.09% Quick Ratio1.40 Sales past 5Y10.50% Gross Margin70.30% 52W Low37.12% ATR2.86
Employees30000 Current Ratio1.60 Sales Q/Q33.00% Oper. Margin26.40% RSI (14)55.93 Volatility3.40% 5.57%
OptionableYes Debt/Eq0.91 EPS Q/Q-177.20% Profit Margin13.20% Rel Volume0.91 Prev Close56.90
ShortableYes LT Debt/Eq0.84 EarningsMay 07 BMO Payout74.50% Avg Volume16.53M Price58.25
Recom1.90 SMA2010.18% SMA50-1.61% SMA2006.20% Volume15,268,733 Change2.37%
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-08-20 10:00AM  The No. 1 Pharma Company Nabbed A Key Approval But Is It A Buy? Investor's Business Daily
06:59AM  Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer Business Wire
Apr-07-20 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
06:59AM  Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. Business Wire
Apr-06-20 10:03PM  Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod Zacks
08:00AM  Pfizer's Upjohn Combo With Mylan Is Delayed What That Means For PFE Stock Investor's Business Daily
Apr-03-20 05:08PM  U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Business Wire
11:08AM  Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks Zacks
10:57AM  Fate Therapeutics Surges on Immunotherapy Deal With J&J Zacks
Apr-02-20 11:05AM  Top Ranked Income Stocks to Buy for April 2nd Zacks
06:30AM  With $1.1B in hand, life sciences investor Flagship rewrites its rulebook American City Business Journals
05:35AM  Heres what a team of Citi analysts say will save the global economy and the stock market MarketWatch
Apr-01-20 05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -1.58%: What You Should Know Zacks
11:50AM  Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA Zacks
06:00AM  Buybacks Are Coming Under Pressure. These Stocks Could Suffer. Barrons.com
Mar-31-20 05:15PM  Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga
04:40PM  Bristol Myers Pops As Key Payout For Celgene Investors Looks Secure Investor's Business Daily
11:40AM  BMY or AZN: Which Is the Better Value Stock Right Now? Zacks
11:07AM  Top Ranked Income Stocks to Buy for March 31st Zacks
06:59AM  Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA Business Wire
Mar-30-20 06:06PM  FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com
11:45AM  Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice Zacks
Mar-29-20 11:49AM  Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic MarketWatch
Mar-28-20 08:04AM  Is It Smart To Buy Bristol-Myers Squibb Company (NYSE:BMY) Before It Goes Ex-Dividend? Simply Wall St.
Mar-27-20 11:18AM  Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia Zacks
11:05AM  Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease Business Wire
11:00AM  Big Pharma and Biotech Need to Do More in the Fight Against Covid-19 Barrons.com
08:14AM  Drugmaker Vertex to delay new clinical studies due to coronavirus Reuters
Mar-26-20 06:58PM  Coronavirus update: Global case count 526,044 with 23,709 deaths, and jobless benefit seekers soar to historic levels MarketWatch +5.88%
06:07PM  Infinity's IPI-549 Gets Fast Track Tag for Urothelial Cancer Zacks
04:24PM  How Bristol Myers' New MS Drug Has A Leg-Up On A Rival From Novartis Investor's Business Daily
03:47PM  UnitedHealth Group rolls out coronavirus testing kits Yahoo Finance Video
12:36PM  Biotech delays U.S. gene therapy launch due to outbreak, FDA discord American City Business Journals
12:18PM  Stocks higher despite dire jobs report after Senate approves historic $2 trillion coronavirus relief bill MarketWatch
10:22AM  Bristol-Myers Wins Green Light for New MS Drug TheStreet.com
10:07AM  Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores Zacks
08:23AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger Benzinga
07:57AM  Bristol-Myers Squibb's new MS drug is approved, launch delayed due to COVID-19 MarketWatch
06:59AM  New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia Business Wire
06:58AM  Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020 Business Wire
06:40AM  U.S. FDA approves Bristol-Myers multiple sclerosis drug Reuters
06:30AM  U.S. Food and Drug Administration Approves Bristol Myers Squibbs ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis Business Wire
Mar-25-20 04:17PM  Will The FDA Approve Bristol's MS Drug? Here Are Some Bullish Indicators Investor's Business Daily
02:45PM  China Suspends Use of BeiGene Cancer Drug Abraxane TheStreet.com
09:58AM  China suspends Bristol-Myers' cancer drug sales over findings at U.S. plant Reuters
09:58AM  China suspends Bristol-Myers' cancer drug over findings at U.S. plant Reuters
09:11AM  China suspends sales of Bristol-Myers' cancer drug Reuters
Mar-24-20 05:35PM  Peninsula biotech scores $80M upfront in potential $1.6 billion cancer drug deal American City Business Journals +6.12%
07:28AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, BHP, CVS Health, T-Mobile US and Anthem Zacks
Mar-23-20 01:53PM  Top Research Reports for Bristol-Myers, BHP & CVS Zacks
11:09AM  Bristol Myers puts new clinical trials on hold due to coronavirus Reuters
06:59AM  Bristol-Myers Squibb Postpones April 2, 2020 Investor Day Business Wire
Mar-22-20 11:02AM  These low-volatility stocks have outperformed during the coronavirus crash MarketWatch
Mar-20-20 08:02PM  Seth Klarman Sees Bargains as the Market Heads Further Into Chaos GuruFocus.com
05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -0.8%: What You Should Know Zacks
Mar-19-20 11:30AM  Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound? Zacks
Mar-18-20 06:59AM  Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development Business Wire -7.12%
Mar-16-20 04:18PM  BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug Investor's Business Daily -7.06%
Mar-13-20 04:22PM  Celgene Corporation -- Moody's withdraws Celgene's ratings Moody's
11:24AM  All-or-Nothing Bet on New Bristol Myers Drugs Faces First Test Bloomberg
Mar-12-20 04:09PM  How a $27 Billion Fund Finds Quality Dividend Stocks Barrons.com -6.65%
10:19AM  Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC Zacks
Mar-11-20 01:13PM  Harry Potter publishers stock climbs as Britains chancellor waves his magic wand MarketWatch
11:45AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks
11:22AM  Pharma M&A Has Slowed to a Crawl GuruFocus.com
07:16AM  U.S. FDA approves Bristol Myers' liver cancer therapy Reuters
06:59AM  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib Business Wire
Mar-10-20 04:28PM  5 Top Stock Trades for Wednesday: AMZN, DKS, AAL, BMY, UAL InvestorPlace
09:50AM  Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study Zacks
Mar-09-20 04:17PM  Bristol-Myers Squibb Dips After Cancer Treatment Flops In Key Test Investor's Business Daily
03:19PM  Eli Lilly and 2 More Drug Stocks That Could Ride Out the Coronavirus Crisis, According to J.P. Morgan Barrons.com
12:15PM  Bristol-Myers Squibb Dips After Cancer Treatment Flops In Key Test Investor's Business Daily
07:12AM  Bristol-Myers' multiple myeloma combo therapy fails late-stage study Reuters
07:10AM  Bristol-Myers shares slide 4% premarket on news of failed trial of multiple myeloma treatment MarketWatch
06:59AM  Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma Business Wire
Mar-07-20 11:30AM  Why Is Bristol-Myers (BMY) Down 10.1% Since Last Earnings Report? Zacks
10:31AM  Coronavirus Outbreak Could Disrupt Drug Companies Clinical Trials Barrons.com
Mar-05-20 05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know Zacks
12:27PM  Biopharma Could Outperform Volatile Market, Analyst Says Barrons.com
08:30AM  Bristol-Myers Named a Bank of America Top Pick Amid Coronavirus Fallout TheStreet.com
Mar-04-20 11:12AM  Coronavirus vaccine could add billions in value to this one stock Yahoo Finance
11:00AM  These 4 Pharma Stocks Are Outplaying 90% Of The Stock Market Investor's Business Daily
10:43AM  Hedge Funds Have Never Been This Bullish On Bristol Myers Squibb Company (BMY) Insider Monkey
Mar-03-20 05:30PM  Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology Business Wire
05:00AM  Fidelity De-FANGs- A Shift in Stock Exposure MoneyShow
Mar-02-20 08:52PM  CORRECTING and REPLACING BristolMyers Squibb Announces Dividend Business Wire
04:46PM  Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Benzinga
Feb-28-20 05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -0.87%: What You Should Know Zacks
08:15AM  Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
Feb-27-20 11:41AM  Seth Klarman Increases His Favorite Holdings in the 4th Quarter GuruFocus.com
09:54AM  New bill aims to protect medical product supply chain amid coronavirus outbreak Yahoo Finance Video
06:59AM  Bristol-Myers Squibb Company Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
05:45AM  New bill aims to protect medical product supply chain amid coronavirus outbreak Yahoo Finance
Feb-24-20 11:45AM  Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? Zacks
Feb-21-20 12:13PM  Ronald Muhlenkamp's Firm Buys 3 Stocks in 4th Quarter GuruFocus.com
06:59AM  Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer Business Wire
Feb-20-20 04:51PM  4 Most Popular Healthcare Stocks Among Hedge Funds: Q4 Rankings Insider Monkey
12:37PM  David Abrams Buys 2 Stocks in 4th Quarter GuruFocus.com
05:00AM  A Portfolio for Steady Dividends MoneyShow
Feb-19-20 10:29AM  Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake American City Business Journals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in hematology, oncology, immunology, cardiovascular, and fibrotic diseases. It provides Revlimid and Pomalyst/Imnovid, which are oral immunomodulatory drugs used to treat multiple myeloma; Eliquis, an oral inhibitor for stroke prevention and venous thromboembolic disorders; Opdivo, a biological product for anti-cancer indications; and Orencia, a biological product for patients with active RA and prostate-specific antigen and active polyarticular juvenile idiopathic arthritis. The company also offers Sprycel, a tyrosine kinase inhibitor to treat Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody to treat unresectable or metastatic melanoma; Abraxane, a chemotherapy product used to treat breast, non-small cell lung, and pancreatic cancers; and Reblozyl, an erythroid maturation agent to treat anemia. In addition, it provides Inrebic, a kinase inhibitor to treat myelofibrosis; Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Baraclude, an oral antiviral agent to treat chronic hepatitis B; and Vidaza, a pyrimidine nucleoside analog to treat refractory anemia and chronic myeloid leukemia. The company sells products to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities, and medical profession. Bristol-Myers Squibb Company has collaboration agreements with Ono; AbbVie; Nektar Therapeutics; Five Prime Therapeutics, Inc.; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Nitto Denko Corporation; GeMoaB Monoclonals GmbH; bluebird bio, Inc.; Acceleron Pharma Inc.; Agios Pharmaceuticals, Inc.; Ikena Oncology, and Pfizer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0012,373026,281Jan 03 07:00 PM
VESSEY RUPERTPres., Research & Early Dev.Dec 31Option Exercise0.0016,060030,778Jan 03 07:00 PM
Dubow AdamChief Compliance & Ethics OffiDec 05Sale58.811,740102,32915,749Dec 09 04:44 PM
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyNov 05Sale56.5625,0001,414,00031,963Nov 06 04:54 PM
Elicker John ESVP, Public Affairs & IRNov 05Sale56.6615,000849,90074,471Nov 06 04:54 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.0059206,417Oct 03 04:46 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064103,707Sep 04 05:17 PM
BERTOLINI ROBERT JDirectorJul 31Buy44.7211,000491,92011,397Aug 01 05:06 PM
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM